Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D
Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas, USA.
Oncology (Williston Park). 1995 Dec;9(12):1321-8; 1331; discussion 1332-4.
A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; and the paclitaxel analog docetaxel. The authors discussed these new agents last month. In Part 2 of their article, they describe gemcitabine, an antimetabolite structurally related to cytarabine; fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors, and new approaches to anticancer therapy, such as angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.
